Skip Navigation LinksHome > April 2014 - Volume 21 - Issue 4 > Efficacy of omega-3 for vasomotor symptoms treatment: a ran...
doi: 10.1097/GME.0b013e31829e40b8
Original Articles

Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial

Cohen, Lee S. MD1; Joffe, Hadine MD, MSc1; Guthrie, Katherine A. PhD2; Ensrud, Kristine E. MD3; Freeman, Marlene MD1; Carpenter, Janet S. PhD, RN, FAAN4; Learman, Lee A. MD, PhD5; Newton, Katherine M. PhD6; Reed, Susan D. MD, MPH7; Manson, JoAnn E. MD, DrPH8; Sternfeld, Barbara PhD9; Caan, Bette DrPH9; Freeman, Ellen W. PhD10; LaCroix, Andrea Z. PhD2; Tinker, Lesley F. PhD2; Booth-LaForce, Cathryn PhD11; Larson, Joseph C. MS2; Anderson, Garnet L. PhD2

Supplemental Author Material
Collapse Box


Objective: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women.

Methods: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician’s Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7).

Results: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (−2.5; 95% CI, −3.0 to −1.9) did not differ significantly from that with placebo (−2.7; 95% CI, −3.3 to −2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI, −0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI, −0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons).

Conclusions: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.

© 2014 by The North American Menopause Society.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.